Seelos Therapeutics EPS - Earnings per Share 2010-2022 | SEEL

Seelos Therapeutics eps - earnings per share from 2010 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Seelos Therapeutics Annual EPS
2021 $-0.73
2020 $-0.43
2019 $-2.52
2018 $-1.13
2017 $0.81
2016 $-34.54
2015 $-115.02
2014 $-165.17
2013 $-147.15
2012 $-348.35
2011 $-270.27
2010 $-747.75
2009 $-108.11
Seelos Therapeutics Quarterly EPS
2022-03-31 $-0.13
2021-12-31 $-0.24
2021-09-30 $-0.11
2021-06-30 $-0.10
2021-03-31 $-0.28
2020-12-31 $-0.12
2020-09-30 $-0.09
2020-06-30 $-0.08
2020-03-31 $-0.14
2019-12-31 $1.68
2019-09-30 $-0.13
2019-06-30 $-0.09
2019-03-31 $-3.98
2018-12-31 $-0.40
2018-09-30 $-0.36
2018-06-30 $-0.16
2018-03-31 $-0.21
2017-12-31 $-17.81
2017-09-30 $-8.71
2017-06-30 $-3.90
2017-03-31 $31.23
2016-12-31 $15.92
2016-09-30 $-5.71
2016-06-30 $-16.22
2016-03-31 $-28.53
2015-12-31 $-15.92
2015-09-30 $-30.03
2015-06-30 $-30.03
2015-03-31 $-39.04
2014-12-31 $-129.13
2014-09-30 $-24.02
2014-06-30 $15.02
2014-03-31 $-27.03
2013-12-31 $-12.01
2013-09-30 $-24.02
2013-06-30 $-36.04
2013-03-31 $-87.09
2012-12-31 $-198.20
2012-09-30 $-27.03
2012-06-30 $-57.06
2012-03-31 $-60.06
2011-12-31 $-66.07
2011-09-30 $-33.03
2011-06-30 $-117.12
2011-03-31 $-54.05
2010-12-31 $-222.22
2010-09-30 $-60.06
2010-06-30 $-141.14
2010-03-31 $-360.18
2009-12-31 $-102.10
2009-09-30 $-45.02
2009-06-30 $-90.05
2009-03-31 $45.02
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.106B $0.000B
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $153.995B 9.34
GSK (GSK) United Kingdom $82.506B 9.91
Bio-Rad Laboratories (BIO.B) United States $16.008B 35.37
QIAGEN (QGEN) Netherlands $11.286B 18.90
Biohaven Pharmaceutical Holding (BHVN) United States $10.366B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.454B 0.00
Arcus Biosciences (RCUS) United States $1.972B 38.49
Emergent Biosolutions (EBS) United States $1.578B 9.15
Myovant Sciences (MYOV) United Kingdom $1.450B 0.00
Zymeworks (ZYME) Canada $0.376B 0.00
Enzo Biochem (ENZ) United States $0.123B 0.00
Gelesis Holdings (GLS) United States $0.098B 0.00
SQZ Biotechnologies (SQZ) United States $0.095B 0.00
Ambrx Biopharma (AMAM) United States $0.091B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00